Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis

References

• Akizuki S, Nakazato O, Higuchi Y, Tanabe K, Setoguchi M, Yoshida S, Miyazaki Y, Yamamoto S, Sudou S, Sannomiya K, Okajima T. Necropsy findings in HTLV-I associated myelopathy. Lancet 1987; i: 156
   Google Scholar
• Cruickshank J K, Rudge P, Dalgleish A G, Newton M, McLean B N, Barnard R O, Kendall B E, Miller D H. Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain 1989; 112: 1057–1090
   PubMed Web of Science ®Google Scholar
• Duncan J, Rudge P. Methylprednisolone therapy in tropical spastic paraparesis. J Neurol Neurosurg Psychiatry 1990; 53: 173–174
   PubMed Web of Science ®Google Scholar
• Faden A I, Jacob T P, Holady J W. Thyrotropinreleasing hormone improves neurologic recovery after spinal trauma in cats. New Engl J Med 1981; 305: 1063–1067
   PubMed Web of Science ®Google Scholar
• Gessain A, Barin F, Vernant J C, Grout O, Maurs L, Calender A, de The G. Antibodies to human Tlymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; ii: 407–409
   Google Scholar
• Gessain A, Gout O. Chronic myelopatiiy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1992; 117: 933–946
   PubMed Web of Science ®Google Scholar
• Gout O, Gessain A, Bolgert F, Saal F, Tournier-Lasserve E, Lasneret J, Caudie C, Brunet P, De-The G, Lhermitte F, Lyon-Caen O. Chronic myelopathies associated widi human T-lymphotropic virus type I. A clinical, serologic, and immunovirologic study of ten patients in France. Arch Neurol 1989; 46: 255–260
   Google Scholar
• Hara H, Morita M, Iwaki T, Hatae T, Itoyama Y, Kitamoto T, Akizuki S, Goto I, Watanabe T. Detection of human T lymphotrophic virus type I (HTLV-I) proviral DNA and analysis of T cell receptor V β CDR sequences in spinal cord lesions of HTLV-Iassociated myelopathy/tropical spastic paraparesis. J Exp Med 1994; 180: 831–839
   Google Scholar
• Harrington W J, Jr, Sheremata W A, Snodgrass S R, Emerson S, Phillips S, Berger J R. Tropical spastic paraparesis/HTLV-1-associated myelopathy (HAM/TSP): treatment with an anabolic steroid danazol. AIDS Res Hum Retroviruses 1991; 7: 1031–1034
   PubMed Web of Science ®Google Scholar
• Ichinose K, Nakamura T, Kawakami A, Eguchi K, Nagasato K, Shibayama K, Tsujihata M, Nagataki S. Increased adherence of T cells to human endothelial cells in patients with human T-cell lymphotropic virus type I-associated myelopathy. Arch Neurol 1992; 49: 74–76
   PubMed Web of Science ®Google Scholar
• Ijichi S, Eiraku N, Osame M, Izumo S, Kubota R, Maruyama I, Matsumoto M, Sonoda S. In vitro modulation of lymphocyte proliferation by prednisolone and interferon-alpha in patients with HTLV-I associated myelopatiiy (HAM). J Neuroimmunol 1989a; 23: 175–178
   Google Scholar
• Ijichi S, Eiraku N, Osame M, Izumo S, Kubota R, Maruyama I, Matsumoto M, Niimura T, Sonoda S. Activated T lymphocytes in cerebrospinal fluid of patients with HTLV-I-associated myelopathy (HAM/TSP). J Neuroimmunol 1989b; 25: 251–254
   Google Scholar
• Ijichi S, Izumo S, Eiraku N, Machigashira K, Kubota R, Nagai M, Ikegami N, Kashio N, Umehara I, Osame M. An autoaggressive process against bystander tissues in HTLV-I-infected individuals: a possible pathomechanism of HAM/TSP. Medical Hypotheses 1993; 41: 542–547
   Google Scholar
• Itoyama Y, Minato S, Kira J, Goto I, Sato H, Okochi K, Yamamoto N. Altered subsets of peripheral blood lymphocytes in patients with HTLV-I associated myelopathy (HAM). Neurology 1988a; 38: 816–818
   PubMed Web of Science ®Google Scholar
• Itoyama Y, Minato S, Kira J, Goto I, Sato H, Okochi K, Yamamoto N. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology 1988b; 38: 1302–1307
   PubMed Web of Science ®Google Scholar
• Iwasaki Y. Pathology of chronic myelopathy associated with HTLV-l infection (HAM/TSP). J Neurol Sci 1990; 96: 103–123
   Google Scholar
• Iwasaki Y, Ohara Y, Kobayashi I, Akizuki S. Infiltration of helper/inducer T lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection. Am J Pathol 1992; 140: 1003–1008
   PubMed Web of Science ®Google Scholar
• Izumo S, Usuku K, Osame M, Arimura K, Igata A. Effect of alpha-interferon treatment on HTLV-I associated myelopathy (HAM). Neurology 1988; 38(Suppl 1)242
   Google Scholar
• Jacobson S, Shida H, McFarlin D E, Fauci A S, Koening S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990; 348: 245–248
   PubMed Web of Science ®Google Scholar
• Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G, Sato S, Morita M, Kidokoro M, Sugimoto M, Funahashi S, Osame M, Shida H. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLVI-infected cells. Int Immunol 1991; 3: 761–767
   PubMed Web of Science ®Google Scholar
• Kataoka A, Imai H, Inayoshi S, Tsuda T. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psychiatry 1993; 56: 1213–1216
   PubMed Web of Science ®Google Scholar
• Kira J, Fujihara K, Itoyama Y, Goto I, Hasuo K. Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a 2 year follow-up study after corticosteroid therapy. J Neurol Sci 1991; 106: 41–4
   Google Scholar
• Kuroda Y, Takashima H. Impairment of cellmediated immune responses in HTLV-I-associated myelopadiy. J Neurol Sci 1990; 100: 211–216
   Google Scholar
• Kuroda Y, Kurohara K, Fujiyama F, Takashima H, Endo C, Matsui M, Neshige R, Kakigi R. Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol Scand 1992; 86: 82–86
   Google Scholar
• Lehky T J, Fox C H, Koenig S, Levin M C, Flerlage N, Izumo S, Sato E, Raine C S, Osame M, Jacobson S. Detection of human T-lymphotropic virus type I (HTLV-I) Tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol 1995; 37: 167–175
   PubMed Web of Science ®Google Scholar
• Matsuo H, Nakamura T, Tsujihata M, Kinoshita I, Satoh A, Tomita I, Shirabe S, Shibayama K, Nagataki S. Plasmapheresis in treatment of human Tlymphotropic virus type-I associated myelopathy. Lancet 1988; ii: 1109–1113
   Google Scholar
• Matsuo H, Nakamura T, Shibayama K, Nagasato K, Tsujihata M, Nagataki S. Long-term follow-up of immunomodulation in treatment of HTLV-Iassociated myelopathy. Lancet 1989; i: 790
   Google Scholar
• Morikawa K, Oseko F, Morikawa S. Immunomodulatory effect of fosfomycin on human B-lymphocyte function. Antimicrob Agents Chemother 1993a; 37: 270275
   Google Scholar
• Morikawa K, Oseko F, Morikawa S, Sawada M. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1993b; 37: 2684–2687
   PubMed Web of Science ®Google Scholar
• Nagasato K, Nakamura T, Ichinose K, Nishiura Y, Ohishi K, Shibayama K, Watanabe H, Tsujihata M, Nagataki S. Heparin treatment in patients with human T-lymphotropic virus type I (HTLV-I)-associated myelopathy: a preliminary study. J Neurol Sci 1993; 115: 161–168
   Google Scholar
• Nakagawa M, Izumo S, Ijichi S, Kubota H, Arimura K, Kawabata M, Osame M. HTLV-I-associated myelopathy: Analysis of 213 patients based on clinical features and laboratory findings. Neuro Virology 1995; 1: 50–61
   PubMed Web of Science ®Google Scholar
• Nakamura T, Shibayama K, Nagasato K, Matsuo H, Tsujihata M, Nagataki S. The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy. Jpn J Med 1990; 29: 362–367
   Google Scholar
• Nishimoto N, Yoshizaki N, Eiraku K, Machigashira K, Tagoh H, Ogata A, Kuritani T, Osame M, Kishimoto T. Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/ tropical spastic paraparesis. J Neurol Sci 1990; 97: 183–193
   PubMed Web of Science ®Google Scholar
• Nomoto M, Utatsu Y, Soejima Y, Osame M. Neopterin in cerebrospinal fluid: A useful marker for diagnosis of HTLV-I associated myelopathy/tropical spastic paraparesis. Neurology 1991; 41: 457
   Google Scholar
• Osame M, Matsumoto M, Ijichi S, Rosales R, Niina K, Kashio N, Kawatsu M, Nagata K, Takenaga S, Machigashira K, Matsubara H, Usuku K, Izumo S, Igata A. In vitro removal of anti-HTLV-I antibodies with a new immunoadsorbent from the sera of HTLV-I-associated myelopathy patients. Acta Med Univ Kagoshima 1986; 28: 105–109
   Google Scholar
• Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, Tara M, Igata A. Chronic progressive myelopathy associated with elevated antibodies to HTLV-I and adult T-cell leukemia-like cells. Ann Neurol 1987; 21: 117–122
   PubMed Web of Science ®Google Scholar
• Osame M, Igata A, Matsumoto M, Kohka M, Usuku K, Izumo S. HTLV-I-associated myelopathy (HAM), treatment trials, retrospective survey and clinical laboratory findings. Hematol Rev 1990a; 3: 271–284
   Google Scholar
• Osame M, Janssen R, Kubota H, Nishitani H, Igata A, Nagataki S, Mori M, Goto I, Shimabukuro H, Khabbaz R, Kaplan J. Nationwide survey of HTLV-Iassociated myelopathy in Japan: association with blood transfusion. Ann Neurol 1990b; 28: 50–56
   PubMed Web of Science ®Google Scholar
• Osame M. HAM/TSP: Global review and WHOdiagnostic guidelines. Advances in Neurology, J S Chopra. Elsevier Science Publishers, Amsterdam 1991; 265–271
   Google Scholar
• Osame M, McArthur J C. Neurological manifestations of infection with human T cell lymphotropic virus type I. Diseases of the nervous system: clinical neurobiology, 2nd ed., A K Asbury, et al. WB Saunders, Philadelphia 1992; vol 2: 1331–1339
   Google Scholar
• Sheremata W A, Benedict D, Squilacote D C, Sazant A, DeFreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology 1993; 43: 2125–2129
   PubMed Web of Science ®Google Scholar
• Shibayama K, Nakamura T, Nagasato K, Shirabe S, Tsujihata M, Nagataki S. Interferon-alpha treatment in HTLV-I-associated myelopathy. Studies of clinical and immunological aspects. J Neurol Sci 1991; 106: 186–192
   Google Scholar
• Sugimoto M, Matsumoto M, Imamura F, Nakashima H, Uyama E, Araki S. Effects of erythromycin on lymphocyte function in patients with HTLV-Iassociated myelopathy. Jpn J Inflammation (in Japanese) 1990; 10: 387–391
   Google Scholar
• Takenaga S, Kawahigashi Y, Sonoda Y, Horikiri T, Hirata K, Arimura K, Osame M. Treatment of spastic paraparesis with botulinum toxin with reference to beneficial effects, disease severity and long-term treatment. Clin Neurol (in Japanese) 1995; 35: 251–255
   Google Scholar
• Tendler C, Greenberg S J, Blattner W A, Manns A, Murphy E, Fleisher T, Hanchard B, Morgan O, Burton J D, Nelson D L, Waldmann T A. Transactivation of interleukin 2 and its receptor induces immune activatin in human T-cell lymphotropic virus type I-associated myelopathy: Pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci 1990; 87: 5218–5222
   PubMed Web of Science ®Google Scholar
• Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human Tlymphotropic virus type I-associated myelopathy. Ann Neurol 1993; 33: 646–649
   PubMedGoogle Scholar
• Umehara F, Izumo S, Nakagawa M, Ronquillo A T, Takahashi K, Matsumuro K, Sato E, Osame M. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-Iassociated myelopathy. J Neuropathol Exp Neurol 1993; 52: 424–430
   Google Scholar
• Umehara F, Izumo S, Ronquillo A T, Matsumuro K, Sato E, Osame M. Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 1994a; 53: 72–77
   PubMedGoogle Scholar
• Umehara F, Nakamura A, Izumo S, Kubota R, Ijichi S, Kashio N, Hashimoto K, Usuku K, Sato E, Osame M. Apoptosis-of T lymphocytes in the spinal cord lesions in HTLV-I-associated myelopathy: a possible mechanism to control viral infection in the central nervous system. J Neuropathol Exp Neurol 1994b; 53: 617–624
   Google Scholar
• Usuku K, Sonoda S, Osame M, Yashiki S, Takahashi K, Matsumoto M, Sawada T, Tsuji K, Tara M, Igata A. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: Comparison with adult T-cell leukemia/ lymphoma. Ann Neurol 1988; 23(suppl)sl43–sl50
   Google Scholar
• Vaidyanathan S, Rao M S, Sharma P L, Sachdeva N K. Modulation of urinary bladder infection with thyrotropin-releasing hormone in patients with spinal cord injuries during the spinal shock phase. Ann Clin Res 1983; 15: 66–70
   Google Scholar
• Vernant J C, Maurs L, Gessain A, Barin F, Gout O, Delaporte J M, Sanhadji K, Buisson G, de-The G. Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases. Ann Neurol 1987; 21: 123–130
   Google Scholar
• Yoshida M, Osame M, Kawai H, Toita M, Kuwasaki N, Nishida Y, Hiraki Y, Takahashi K, Nomura K, Sonoda S, Eiraku N, Ijichi S, Usuku K. Increased replication of HTLV-I in HTLV-I-associated myelopathy. Ann Neurol 1989; 26: 331–335
   PubMed Web of Science ®Google Scholar